The Medicines Evaluation Unit was a major participating centre in a study with Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases.

This week, Verona has announced positive Phase 2 data with a pressurized metered-dose inhaler formulation of ensifentrine in patients with moderate to severe COPD for this study.